In the last trading session, 1.45 million shares of the Protalix BioTherapeutics Inc (AMEX:PLX) were traded, and its beta was -0.13. Most recently the company’s share price was $1.56, and it changed around -$0.06 or -3.70% from the last close, which brings the market valuation of the company to $124.18M. PLX currently trades at a discount to its 52-week high of $3.10, offering almost -98.72% off that amount. The share price’s 52-week low was $0.82, which indicates that the current value has risen by an impressive 47.44% since then. We note from Protalix BioTherapeutics Inc’s average daily trading volume that its 10-day average is 1.06 million shares, with the 3-month average coming to 940.81K.
Protalix BioTherapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended PLX as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight.
Protalix BioTherapeutics Inc (AMEX:PLX) trade information
Instantly PLX has showed a red trend with a performance of -3.70% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.7900 on recent trading dayincreased the stock’s daily price by 12.85%. The company’s shares are currently down -17.02% year-to-date, but still down -7.14% over the last five days. On the other hand, Protalix BioTherapeutics Inc (AMEX:PLX) is -45.26% down in the 30-day period. We can see from the shorts that 1.0 million shares have been sold at a short interest cover period of 1.34 day(s).
PLX Dividends
Protalix BioTherapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-08.
Protalix BioTherapeutics Inc (AMEX:PLX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 10.39% of Protalix BioTherapeutics Inc shares, and 10.77% of them are in the hands of institutional investors. The stock currently has a share float of 12.02%. Protalix BioTherapeutics Inc stock is held by 76.0 institutions, with MILLENNIUM MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 1.1106% of the shares, which is about 0.81 million shares worth $0.95 million.
RENAISSANCE TECHNOLOGIES LLC, with 1.1016% or 0.8 million shares worth $0.94 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Unified Series Trust-AUER GROWTH FUND and Bridgeway Funds, Inc.-Ultra-Small Company Market Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 200.0 shares worth $0.31 million, making up 0.25% of all outstanding shares. On the other hand, Bridgeway Funds, Inc.-Ultra-Small Company Market Fund held roughly 180.0 shares worth around $0.28 million, which represents about 0.23% of the total shares outstanding.
